Member Info for dactions

Thanks eekorehc - for TW full report - whatever one thinks about him, he does have a way of writing in a very positive fashion, stuff we already know ! It will help momentum and bring in new investors - which in turn will hopefully encourage CG to keep up the good work.

I agree with all your sentiments Bickmaster84. With all the cash resources they have following the placings including the large BOD purchases and the buy-in with the Woodbois guys at 19p, this has to be good - as you say "one of the most underated stocks on AIM. The sp has slipped on lack of news but when figures come, I'm confident they will be good and show the potential. The team I met at the April Investor show inc. Miles chairman were all feeling very confident that they have the right vehicle in the right market. I'm very hopeful on this one.

Agree with you CTW2014 about averaging down - what I meant was that to a large extent FOX has been in slow and remorseless decline for years - I'm expecting now as the turnaround and there will be steady upward trend. I do agree with you about CG and further placings. I'm sure he knows that now is the time to grow the business without further dilution and above all - get those orders in.

I saw brief comments today from TW at share prophets that bad news could be expected this week - make of that what you will.

dhlindy - it was good to read your past posts on FOX - I wasn't posting on the LSE site for FOX so unaware you saw the factory last December. I wish I had as your posts answered many things which if I'd known before I'd have prioritised my investment here rather than other stocks. I came into FOX end of 2013 at 20p when I met Chris Gilbert at an investment seminar. I topped up at their peak June 2015 at 25p (it still hurts) and of course it's been a slow decline ever since and so no one in FOX can say they're averaging down. However, I've now doubled my stake in recent weeks around the floor of 8/9p as I feel this is now the turning point. Chris Gilbert is a nice bloke and I'm sure firmly believes in the Company's prospects and will want to see the shareprice higher so he can show his previous big backers (placings 20p, 16.5p, 18p, 20p, and lastly 10p) that they've not backed a pup. And of course earn a comfortable retirement for himself. Trading in FOX shares I think is a thin market so upward momentum is very easily possible. But we're nearing the end of this financial year and I'm wondering has there been enough evidence that decent cash flow has been achieved as I dfon't think we'll get any concrete figures for some time yet ? It's been placings every year since the 2012 IPO except 2017 - do you think they can get by without more cash raising ?

Don't know who GS is Trurotrader - but if you meant Chris Gilbert - then he has stuck with it all these years and we may well be on to something big at last. I'm a LTH myself but have rarely commented about Fox as it has been a disappointment for most of us. From an original IPO raising �9.65m at 20p a share, there was a promise of building the factory within 10 months. There was then a placing every year at 16.5p, 18p, 20p and finally last year at 10p ! We've now gone all this time since on loans and modest cash flow. The promised factory was finally fully commisioned only in April this year - so 4 years against 10 months. I bought in around the 20p mark and even bought some at a peak of 25p so for many of us there's history and a good way to go yet. Chris Gilbert and directors started some time back taking their pay in shares so he's to be commended for keeping the company going. It does now look as this is now the time to get in/or top-up as others have noticed the momentum buiding - not least TW at share prophets. I only saw their headline as I don't subscribe but it confirms what we've seen recently. Quote: Fox Marble � new US sale & further shipments to Turkey, momentum continuing to build: BUY Endquote. If anyone does subscribe and can copy the full text that'd be great. In the meantime, I reckon there should be useful figures out for the full year's trading - hopefully CG will give us further updates next month. Remember the marble - and there's lots of it - is effectively free (or in some cases a small license fee paid per tonne extracted). There's not much big business in Kosovo but there is Fox Marble and it enjoys good government support.

One of the questions in yesterday's Fireside chat (not Firearm) event at Sound Energy suggests dealings could be a little later than perhaps we are thinking as in his answer he only mentions early Quarter 1: Question: Hi James, are you able to give any timeframe in which the tie-in with Saffron will be complete and when we will receive our Coro shares? Answer from James Parsons (Chief Executive) Ultimately we expect Sound shareholders to receive their shares early Q1. The sequence is binding agreements shortly, then deal completion early Q1 then the issue of shares.

In Malcy's blog today he praises James Parsons approach with shareholders in Sound Energy: Quote: Sound Energy Whilst writing today�s blog I have been watching the �fireside chat� that Sound Energy have been holding so that their shareholders can be kept up to speed with what their company is up to. Another new development by James Parsons and team who have revolutionised relationships with retail investors in recent years. Unlike a conference call the website opens up to shareholders who have been typing in questions for some time and with CEO, Exploration Director and CFO answering their pretty much every request, a bit like a giant what�s App chat. With well over 600 participants and nearly 200 questions to get through they may be sending out for supplies before long but watching it they seem to have many happy shareholders. Another first #explorersquestiontime Endquote.

This has to be good news from FOX. Many of us were bemoaning the length of time it took to get the Factory completed. But it is now fully operational and the deals we were promised once it was done are now coming through. There's a lot of upward potential in the sp from now on - and not before time really as we patiently waited on news.

Fallingknife - you make vaild points but if a neutral observer was to read both our messages, he/she could decide to buy or sell on whiever interpretation they made. I think we are at the very pivotal point where this goes one way or the other. That's what makes investing exciting. But I shall be looking closely for signs in the weeks ahead for the positives. If I don't see them, then I shall cut my losses.

It's unfair to rubbish Mike Reid (acting CEO) as he has made more share purchases in recent months. At the placing in May he bought �50,000's worth and again in late July another �15000 + worth so that aspect is a good indication of positivity. They've repeated they expect to achieve profitability for the year overall - not breakeven. Quote: The Board is pleased to announce robust growth and believes Falanx is on track to deliver against markets expectations of achieving profitability in the year.Endquote. Cash at halfway is �1million so unless something is seriously wrong with MidGard I don't see why the talk of a further placing (May's was at 6.75p). The big enterprises work on their IT systems revolving around Servers which from my experience are exposed to daily attacks from Eastern Europe and China. If MidGard can disrupt those 24/7 exposures at a reasonable price, then they will succeed in getting customers as the exposure threats are definitely there. I haven't understood where the MicroSOC product to be offered to Small and Medium Sized Businesses fits in unless it's MidGard, albeit in name, and offered at a cheaper price ? I'd like to see for myself MidGard in operation but as that's not going to happen, I have looked at and followed through my understanding of their website advertising. It promises tangible benefits. I have shares in Falanx and recognise that the real profit potential stems from MidGard sales - less so on Consultancy services and the like. I am comfortable at the current level but want to add further given the scope MidGard offers them - I'll be watching for 'positive noises' on MidGard as the sign to buy in more.

That was a wise move by the new acting CEO - there are not many AIM directors willing to put their own money in (relying instead on options). Should support the sp now - but Fallingknife's post is where the negative lies so they've got to get a move on if they're to breakeven or better still show a profit.

Thanks Andyken My own background is IT - one of the reasons I'm in FLX because I can see the need for a company like them and with their new midGard product too. But I was away when news of MB departure came so that was a surprise - haven't digested what that's all about.

I saw a brief comment on the ADVN board that TW has changed his mind having spoken to the company. This was one of their Hot Rockets tips a while back - has anyone here actually seen any reports confirming this please ?

Sorry Rick - if it helps my loss considerably worse. RM2 was boys playing at being businessmen. I've tried to be a bit sharper as a result of my RM2 experience - but having said that I took a punt on Falanx a while back - I go away for a few days and have just come back and seen another horrible mess ! AIM shares are seemingly becoming a one-way bet :-(

Yesterday's RNS never got a mention and the market in general was negative for the smaller AIM stocks. 770k seems small beer for what we're hoping for ?

Thank you Freddie - first time I've personally seen this specific mention of Reneron's work: Below extracted from your link: Quote: And UK-based AIM-listed stem cell therapeutics company ReNeuron plans to exploit exosomes� ability to easily access parts of the body other drug types struggle to reach. They are developing an exosome-based drug for glioblastoma multiforme (GBM), a difficult to treat brain cancer where patients currently have a median life expectancy of just 12-15 months Endquote

After a horrendous experience with RM2 I've tried to learn to be more agile with my share dealings. Yesterday I argued that I was concerned that the market hadn't seen the large dilution following the Spring placing and the previous week was criticised when I aired the massive share options they had given themselves just two/three months ago. I top-sliced at 60p and disposed of my holding Friday at 64p - the markdown since then has been almost 25%. I'd been in Zoo since almost the beginning 2005 and it's been a constant dilution following one placing/funding after another. So, for once I'm quids in. Of course tomorrow Zoo could bounce back (and more !). But some stability around the 50p + mark could be a good thing in the longer term - let its operations and profit generation catch up rather than chase the hype.

Today's RNS for the interim results to September is really very encouraging but I think though the market had got ahead of itself and was maybe expecting even more. My take is that the April placing diluted the shares in issue significantly from 42,647,881 to 78,909,632 so the results have to be seen in that light imho. Hopefully, the sp will be steady in the 50s but will strengthen on future good news.

The October edition of the Edison Healthcare Insight has just been released in which they profile 67 of their healthcare companies under coverage & which this month included RENE. The brief update is here: . INVESTMENT SUMMARY ReNeuron is funded (�53m H117) to undertake pivotal studies with two cell therapy-based programmes. This includes the CTX neural stem cell programme (recently announced a positive end of Phase II meeting with the FDA and intends to go for SPA/RMAT designation for stroke at Phase III) and hRPC (human retinal progenitor cells) programme for retinitis pigmentosa (currently in Phase I/II). It will also be commencing a Phase II trial in cone-rod dystrophy. ReNeuron has promising early data for its exosome nanomedicine platform in oncology. INDUSTRY OUTLOOK Limited drug development has targeted chronic stroke to date, which is the area in which ReNeuron is attempting to demonstrate a meaningful reduction in disability. If shown, it would offer a compelling case for further development and/or partnering. Initial three month follow-up data from its Phase IIa stroke study was sufficiently strong to progress to a pivotal controlled Phase III clinical study in early 2018. http://www.edisoninvestmentresearch.com/serve_pdf.php?d=monthlybooks&f=Edison-Healthcare-Insight-October-2017_low_res.pdf&first_name=Alan&last_name=Essex&company=Private&location=&contact_type=Retail%20Investor&email=alan%40groupmail.com&utm_campaign=982833_Edison%27s%20weekly%20healthcare%20research%20summary%20101117&utm_medium=email&utm_source=Edison%20Investment%20Research%20Limited&dm_i=2PWO,L2CX,2GNKKE,27BXQ,1